Search

Results from a study of women with breast and ovarian cancer show surprisingly low rates of genetic testing.

… Tuesday, July 16, 2019 Summary A recent study in the Journal of Clinical Oncology found that only a quarter of women with breast cancer and a third of women with ovarian cancer had undergone genetic testing. MSK experts say these numbers are surprisingly low. A lot has changed since the BRCA genes were

Over the last seven and a half decades, researchers at the Sloan Kettering Institute have made important contributions to the fundamental understanding of human biology, as well as driven practice-changing innovations in the treatment of cancer.

… Friday, May 19, 2023 When the Sloan Kettering Institute opened its doors on Friday, April 16, 1948, an Associated Press wire story announced: “The world’s greatest cancer center opened here today.” And over the last seven and a half decades, institute researchers have made important contributions to

Brittany Woods, who is completing her doctoral work in the laboratory of physician-scientist Ross Levine, has received a pilot award from the National Cancer Institute that supports outstanding PhD candidates

… Wednesday, October 19, 2016 Brittany Woods , a fifth-year Gerstner Sloan Kettering student, recently received the National Cancer Institute’s Predoctoral to Postdoctoral Fellow Transition Award . This pilot award will support outstanding PhD candidates as they complete their dissertation research and

Doctors and nurses with Memorial Sloan Kettering’s Plastic and Reconstructive Surgical Service have developed new, simplified models to better predict and prevent breast cancer-related lymphedema.

… Thursday, July 27, 2023 Doctors and nurses with  Memorial Sloan Kettering’s Plastic and Reconstructive Surgical Service have developed new, simplified models to better predict and prevent  breast cancer-related lymphedema, an uncomfortable side effect that develops in the months following surgery. Lymphedema

Learn about results from a clinical trial that found blood tests can help predict which patients with large B cell lymphoma are likely to benefit from the targeted therapy glofitamab (Columvi).

… Monday, December 11, 2023 There is encouraging news about using a blood test to determine which patients with aggressive large B cell  lymphoma were most likely to benefit from having the drug glofitamab (Columvi™) added to their treatment. Results from a phase 2 clinical trial (research study) were

Fighting cancer is often sobering and difficult work, but it is also full of hope. Ask anyone who works at MSK what inspires them, and they will tell you it’s the courage and resilience of the people they care for every day.

… Thursday, September 11, 2025 Dear MSK Community, If you ask the 21,000 people who work at MSK what inspires their tireless commitment to our mission of ending cancer for life, you will hear remarkable responses. Stories about the courage and resilience of the people we care for, an epiphany early in

New data reveals that women treated with radiation to the chest for childhood cancer have a high risk of developing breast cancer similar to that of women with BRCA1/2 mutations. The study, led by Memorial Sloan Kettering Cancer Center biostatistician Chaya Moskowitz, PhD, was presented today at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.

… Monday, June 4, 2012 New data reveals that women treated with radiation to the chest for childhood cancer have a high risk of developing breast cancer similar to that of women with BRCA1/2 mutations. The study, led by Memorial Sloan Kettering Cancer Center biostatistician Chaya Moskowitz, PhD , was presented

Learn more about the work of MSK lymphoma researchers being presented at the 2019 meeting of the American Society of Hematology.

… Sunday, December 8, 2019 Summary MSK researchers report advances in the treatment of various types of lymphoma at the annual meeting of the American Society of Hematology. The American Society of Hematology (ASH) annual meeting is the world’s premier event devoted to the study of blood cancers and disorders

Meet Hillary Esposito, who served in the US Military and is now an administrative assistant in Memorial Sloan Kettering Cancer Center's Department of Medicine.

… Thursday, November 11, 2021 Hillary Esposito lives to challenge herself. “Most people don’t challenge themselves enough,” she says. “I’ve always been adventurous and love the feeling and excitement of taking on something new and knowing that I’m growing as a leader.” Ms. Esposito joined Memorial Sloan

The experimental “smart-bomb” drug rovalpituzumab tesirine (Rova-T) appears safe and shows efficacy in treating patients with advanced small cell lung cancer, according to results from a first-in-human clinical trial to be presented today by a MSK researcher at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago.

… Sunday, June 5, 2016 The experimental “smart-bomb” drug rovalpituzumab tesirine (Rova-T) appears safe and shows efficacy in treating patients with advanced small cell lung cancer (SCLC), according to results from a first-in-human clinical trial to be presented today by a Memorial Sloan Kettering Cancer